EAACI Congress 2023
BackEfficacy and safety of lanadelumab in pediatric patients aged 2 to <12 years: subgroup analyses from the SPRING Study
Sunday 11 Jun, 14:07 PM -
14:14 PM CEST
Hall Y 11+12
Flash Talks